+

WO2006001954A3 - Methods for promoting the formation of platelets and for treating blood and bone marrow disorders - Google Patents

Methods for promoting the formation of platelets and for treating blood and bone marrow disorders Download PDF

Info

Publication number
WO2006001954A3
WO2006001954A3 PCT/US2005/017735 US2005017735W WO2006001954A3 WO 2006001954 A3 WO2006001954 A3 WO 2006001954A3 US 2005017735 W US2005017735 W US 2005017735W WO 2006001954 A3 WO2006001954 A3 WO 2006001954A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
bone marrow
promoting
platelets
treating blood
Prior art date
Application number
PCT/US2005/017735
Other languages
French (fr)
Other versions
WO2006001954A2 (en
Inventor
Jonathan G Drachman
Brian J Lannutti
Manish Gandhi
Original Assignee
Puget Sound Blood Ct And Progr
Jonathan G Drachman
Brian J Lannutti
Manish Gandhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puget Sound Blood Ct And Progr, Jonathan G Drachman, Brian J Lannutti, Manish Gandhi filed Critical Puget Sound Blood Ct And Progr
Publication of WO2006001954A2 publication Critical patent/WO2006001954A2/en
Publication of WO2006001954A3 publication Critical patent/WO2006001954A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods for promoting the differentiation of megakaryocytes, methods for forming platelets, and methods for reducing the number of abnormal or malignant cells in bone marrow. In some embodiments, the methods comprise the step of contacting megakaryocyte progenitors with an amount of a 3-(cyclohexanoheteroarylidenyl)-2-indolinone compound effective to promote their differentiation. In some embodiments, the 3-(cyclohexanoheteroarylidenyl)-2-indolinone compound is 2-oxo-3-(4, 5, 6, 7-tetrahydro-lH-indol-2-ylmethylene)-2,3-dihydro-lH-indole-5-sulfonic acid dimethylamide (SU6656). The invention also provides methods for treating blood and bone marrow disorders.
PCT/US2005/017735 2004-05-20 2005-05-20 Methods for promoting the formation of platelets and for treating blood and bone marrow disorders WO2006001954A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57344704P 2004-05-20 2004-05-20
US60/573,447 2004-05-20
US62040204P 2004-10-19 2004-10-19
US60/620,402 2004-10-19

Publications (2)

Publication Number Publication Date
WO2006001954A2 WO2006001954A2 (en) 2006-01-05
WO2006001954A3 true WO2006001954A3 (en) 2006-03-23

Family

ID=35170037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017735 WO2006001954A2 (en) 2004-05-20 2005-05-20 Methods for promoting the formation of platelets and for treating blood and bone marrow disorders

Country Status (1)

Country Link
WO (1) WO2006001954A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434527A (en) 2006-04-14 2017-02-22 安斯泰来再生医药协会 Hemangio-colony forming cells
ATE551542T1 (en) 2007-08-20 2012-04-15 Schaeffler Technologies Ag CLUTCH UNIT
US8933071B2 (en) 2008-11-07 2015-01-13 Northwestern University Dimethyl fasudil for inducing polyploidization of megakaryocytes and for treating blood and bone marrow diseases and disorders
US7897602B2 (en) 2009-01-12 2011-03-01 Development Center For Biotechnology Indolinone compounds as kinase inhibitors
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
US9687486B2 (en) 2012-12-20 2017-06-27 The Trustees Of Columbia University In The City Of New York Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator
CN114558032A (en) 2012-12-21 2022-05-31 安斯泰来再生医药协会 Method and composition for preparing platelets from pluripotent stem cells
WO2014107240A1 (en) 2013-01-03 2014-07-10 Brigham And Women's Hospital, Inc. System and method for a biomimetic fluid processing
US20160067301A1 (en) * 2013-04-12 2016-03-10 The Trustees Of Columbia University In The City Of New York Antagonism of abcg4, lyn kinase, and c-cbl e3 ligase to increase platelet count as therapy for thrombocytopenia
CA2944314C (en) 2014-03-31 2023-09-19 Brigham And Women's Hospital, Inc. Systems and methods for biomimetic fluid processing
KR20210034041A (en) 2018-07-19 2021-03-29 플레이틀렛 바이오제네시스, 인크. Stacked Recirculation Bioreactor
WO2020185856A1 (en) * 2019-03-11 2020-09-17 The Children's Medical Center Corporation Methods for increasing platelet production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045689A2 (en) * 1999-12-22 2001-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045689A2 (en) * 1999-12-22 2001-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLAKE R A ET AL: "SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 20, no. 23, December 2000 (2000-12-01), pages 9018 - 9027, XP002989060, ISSN: 0270-7306 *
BROOME MARTIN A ET AL: "Selective Src family kinase inhibitors as potential therapeutic agents for cancer", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), & 92ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; NEW ORLEANS, LA, USA; MARCH 24-28, 2001, pages 836, XP008059117, ISSN: 0197-016X *
DUEHRSEN U ET AL: "EFFECTS OF VASCULAR ENDOTHELIAL AND PLATELET-DERIVED GROWTH FACTOR RECEPTOR INHIIBITORS ON LONG-TERM CULTURES FROM NORMAL HUMAN BONE MARROW", GROWTH FACTORS, HARWOOD ACADEMIC PUBLISHERS GMBH, vol. 19, no. 1, 2001, pages 1 - 17, XP009020567, ISSN: 0897-7194 *
LANNUTTI BRIAN J ET AL: "Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 797A - 798A, XP008059064, ISSN: 0006-4971 *
LANNUTTI BRIAN J ET AL: "Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656.", BLOOD. 15 MAY 2005, vol. 105, no. 10, 15 May 2005 (2005-05-15), pages 3875 - 3878, XP008059078, ISSN: 0006-4971 *
LANNUTTI BRIAN J ET AL: "Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors", BLOOD, vol. 103, no. 10, 15 May 2004 (2004-05-15), pages 3736 - 3743, XP008059096, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2006001954A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2006001954A3 (en) Methods for promoting the formation of platelets and for treating blood and bone marrow disorders
Lima et al. The role of the substantia nigra pars compacta in regulating sleep patterns in rats
EP1491093A3 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
ATE474569T1 (en) USE OF SPHINGOSINE-1 PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF DEGENERATIVE BRAIN DISEASES
WO2006044860A3 (en) Thiadiazole compounds and methods of use
Delgado-Ruiz et al. Slow drilling speeds for single-drill implant bed preparation. Experimental in vitro study
EP2182063A3 (en) Modulation of EIF4E expression
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Bengazi et al. Osseointegration of implants with dendrimers surface characteristics installed conventionally or with P iezosurgery®. A comparative study in the dog
EA200401284A1 (en) SUBSTITUTED BENZEZOLES AND THEIR APPLICATION AS RAF KINASE INHIBITORS AS AN INHIBITORS
NO20011174L (en) Novel heteroaromatic inhibitors of fructose-1,6-bisphosphotase
WO2006021881A3 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP2674165A3 (en) Hepatocyte growth factor receptor agonist for increasing lymphangiogenesis
EA200702253A1 (en) PHARMACEUTICAL COMPOSITION
EP2289940A3 (en) Treatment of metastatic disease
PL1776349T3 (en) 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
WO2007098142A3 (en) Oxazole ketones as modulators of fatty acid amide hydrolase
Cartford et al. Eighteen-month-old Fischer 344 rats fed a spinach-enriched diet show improved delay classical eyeblink conditioning and reduced expression of tumor necrosis factor α (TNFα) and TNFβ in the cerebellum
WO2005053719A3 (en) Compositions for the treatment of diseases of the oral cavity and upper respiratory tract
Ribeiro et al. Selective cyclooxygenase‐2 inhibitor may impair bone healing around titanium implants in rats
AU2003260436A1 (en) Pyrimidine compounds
WO2004043990A3 (en) Human stem cell materials and methods
Rogliani et al. Smokers: risks and complications in abdominal dermolipectomy
MX2024004801A (en) Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载